Chair: Alexis Borisy, Chairman, Forma Therapeutics, Inc.
Staff Contact: Sara Radcliffe, Executive Vice President, Health Section, email@example.com
Subject Matter/Jurisdiction: The committee oversees BIO’s bioethics work plan objectives to increase public acceptance of biotechnology and research, including stem cell research and therapeutic cloning, and to create opportunities for broader consultation and collaboration with leading bioethics experts to enable BIO to predict and respond to ethical issues that will arise involving the creation and use of new biotechnologies.
Alexis Borisy, Chairman, Forma Therapeutics, Inc.
Jean-Jacques Bienaime, President & CEO, BioMarin Pharmaceutical, Inc.
John Crowley, President & CEO, Amicus Therapeutics, Inc.
Douglas Doerfler, President & CEO, MaxCyte, Inc.
Maxine Gowen, President & CEO, Trevena, Inc.
Glenn Gormley, President, Daiichi Sankyo Pharma Development
Steve Holtzman, Executive VP of Corporate Development, Biogen Idec, Inc.
Rachel King, Chief Executive Officer, GlycoMimetics, Inc.
Thomas Mathers, President & CEO, Peptimmune, Inc.
Arlene Morris, Chief Executive Officer, Syndax
John Orwin, Chief Executive Officer, Affymax, Inc.
Ronald Stotish, Chief Executive Officer, Aqua Bounty Technologies, Inc.
Eddie Sullivan, Chief Operating Officer, Hematech, Inc., a subsidiary of Kirin Pharma
Daniel Tasse, Chairman & CEO, Ikaria